Stock code: 688185 Stock abbreviation:CanSino Announcement No.: 2022-012
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.
I. Overview
The Joint Prevention and Control Mechanism of the State Council held a press conference on February 19, 2022, at which it was announced that, with the approval of the Joint Prevention and Control Mechanism of the State Council, the National Health Commission has begun to deploy sequential booster immunizations of the new crown vaccine.
Previously, all people who were vaccinated with Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, Sinopharm Zhongsheng Wuhan Company inactivated vaccine or CanSinobiological sharesThe adenovirus vector vaccine of the company (hereinafter referred to as the “company”) is targeted to people over 18 years old who have reached the age of 6 months, and can receive one dose of homologous booster immunization, that is, boosting with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of inoculation with the above three inactivated vaccines can also choose Zhifeilong Kema’s recombinant protein vaccine or the company’s adenovirus vector vaccine for sequential booster immunization. For the target population, one of homologous booster immunization and sequential booster immunization can be selected. Whether it is homologous boosting or sequential boosting, it needs to be implemented in people over the age of 18 who have completed the full vaccination for 6 months.
The impact on the company
) (hereinafter referred to as “the product”) has obtained the conditional marketing approval in China and the emergency use authorization in many overseas countries.
After the product is approved for sequential booster immunization, if the relevant state departments subsequently increase its purchases, it will have a certain positive impact on the performance of the listed company.
3. Risk Warning
1. The application for conditional marketing of this product is based on the “Administrative Measures for Drug Registration” (Order No. 27 of the State Administration for Market Regulation) “Article 63 During the clinical trial of drugs, drugs that meet the following conditions may apply for conditional approval: (3) Vaccines urgently needed in response to major public health emergencies or other vaccines deemed urgently needed by the National Health Commission, the benefits outweigh the risks upon evaluation.”
2. After inquiry, up to now, 4 domestic new crown vaccine products have been approved for marketing, 3 have been approved for emergency use, and many are in the clinical trial stage. Even if the product is approved for sequential booster immunization, its future market sales will still face relatively fierce competition, and will be affected by various factors such as the development and changes of domestic and foreign epidemics and the domestic new crown vaccination rate.
3. Investors are advised to make decisions with caution and pay attention to preventing investment risks. The relevant company information is subject to the announcements published by the company’s designated disclosure media “China Securities Journal”, “Securities Times”, “Securities Daily”, “Shanghai Securities News” and the website of the Shanghai Stock Exchange.
Special announcement.
cansino bio co., ltd.
Board of Directors
February 21, 2022
Massive information, accurate interpretation, all in Sina Finance APP